Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis

Sameem Abedin; Nahid Rashid; Mark Schroeder; Rizwan Romee; Mary Nauffal; Muhamad Alhaj Moustafa; Mohamed A. Kharfan-Dabaja; Jeanne Palmer; William Hogan; Mehrdad Hefazi; Samantha Larson; Shernan Holtan; Zachariah DeFilipp; Reena Jayani; Bhagirathbhai Dholaria; Joseph Pidala; Farhad Khimani; Michael R. Grunwald; Candace Butler; Mehdi Hamadani

doi:10.1111/bjh.17700

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis

Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.

Original language	English (US)
Pages (from-to)	429-432
Number of pages	4
Journal	British journal of haematology
Volume	195
Issue number	3
Early online date	Jul 12 2021
DOIs	https://doi.org/10.1111/bjh.17700
State	Published - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd

Keywords

graft-versus-host disease
stem cell transplantation
transplant

Publisher link

10.1111/bjh.17700

Find It

Find It at U of M Libraries

Cite this

Abedin, S., Rashid, N., Schroeder, M., Romee, R., Nauffal, M., Alhaj Moustafa, M., Kharfan-Dabaja, M. A., Palmer, J., Hogan, W., Hefazi, M., Larson, S., Holtan, S., DeFilipp, Z., Jayani, R., Dholaria, B., Pidala, J., Khimani, F., Grunwald, M. R., Butler, C., & Hamadani, M. (2021). Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis. British journal of haematology, 195(3), 429-432. https://doi.org/10.1111/bjh.17700

Abedin, S, Rashid, N, Schroeder, M, Romee, R, Nauffal, M, Alhaj Moustafa, M, Kharfan-Dabaja, MA, Palmer, J, Hogan, W, Hefazi, M, Larson, S, Holtan, S, DeFilipp, Z, Jayani, R, Dholaria, B, Pidala, J, Khimani, F, Grunwald, MR, Butler, C & Hamadani, M 2021, 'Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis', British journal of haematology, vol. 195, no. 3, pp. 429-432. https://doi.org/10.1111/bjh.17700

@article{03a5b8fa5600422eb8eeecf245f650bf,

title = "Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis",

abstract = "Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36\%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50\% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.",

keywords = "graft-versus-host disease, stem cell transplantation, transplant",

author = "Sameem Abedin and Nahid Rashid and Mark Schroeder and Rizwan Romee and Mary Nauffal and \{Alhaj Moustafa\}, Muhamad and Kharfan-Dabaja, \{Mohamed A.\} and Jeanne Palmer and William Hogan and Mehrdad Hefazi and Samantha Larson and Shernan Holtan and Zachariah DeFilipp and Reena Jayani and Bhagirathbhai Dholaria and Joseph Pidala and Farhad Khimani and Grunwald, \{Michael R.\} and Candace Butler and Mehdi Hamadani",

note = "Publisher Copyright: {\textcopyright} 2021 British Society for Haematology and John Wiley \& Sons Ltd",

year = "2021",

month = nov,

doi = "10.1111/bjh.17700",

language = "English (US)",

volume = "195",

pages = "429--432",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis

AU - Abedin, Sameem

AU - Rashid, Nahid

AU - Schroeder, Mark

AU - Romee, Rizwan

AU - Nauffal, Mary

AU - Alhaj Moustafa, Muhamad

AU - Kharfan-Dabaja, Mohamed A.

AU - Palmer, Jeanne

AU - Hogan, William

AU - Hefazi, Mehrdad

AU - Larson, Samantha

AU - Holtan, Shernan

AU - DeFilipp, Zachariah

AU - Jayani, Reena

AU - Dholaria, Bhagirathbhai

AU - Pidala, Joseph

AU - Khimani, Farhad

AU - Grunwald, Michael R.

AU - Butler, Candace

AU - Hamadani, Mehdi

PY - 2021/11

Y1 - 2021/11

N2 - Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.

AB - Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.

KW - graft-versus-host disease

KW - stem cell transplantation

KW - transplant

UR - https://www.scopus.com/pages/publications/85109689194

UR - https://www.scopus.com/inward/citedby.url?scp=85109689194&partnerID=8YFLogxK

U2 - 10.1111/bjh.17700

DO - 10.1111/bjh.17700

M3 - Article

C2 - 34254289

AN - SCOPUS:85109689194

SN - 0007-1048

VL - 195

SP - 429

EP - 432

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this